---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-23-000032"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:41:43.760177+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports FY2022 net loss of $58.2M; cash runway through Q1 2024; IND on track for H2 2023

## Summary
- Cash, cash equivalents & short-term investments of $98.6M as of Dec 31, 2022; expect funding through at least Q1 2024.
- FY2022 net loss $58.2M ($2.23 per share) vs $55.3M ($19.00 per share) in 2021; R&D expenses $34.1M, G&A $40.8M.
- SENTI-202 IND application for AML/MDS planned in H2 2023; preclinical data to be presented at AACR April 2023.
- Capital expenditures of $8.5M in Q4 2022 driven by cGMP manufacturing facility buildout and equipment.
- Collaborations with Spark Therapeutics and BlueRock Therapeutics advancing Gene Circuit programs.

## SEC filing metadata
- accession: 0001854270-23-000032
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/0001854270-23-000032-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/snti-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-23-000032
- JSON: https://secwatch.observer/filing/0001854270-23-000032.json
- Plain text: https://secwatch.observer/filing/0001854270-23-000032.txt

## Key facts
- Earnings Releases
  Senti Biosciences, Inc. reported the year ended December 31, 2022 results: net income Net loss ... $58.2 million, EPS $2.23 per share.
  - Period: the year ended December 31, 2022
  - Net income: Net loss ... $58.2 million
  - EPS: $2.23 per share
  - Result: reported results
  source text: Senti Biosciences, Inc. issued a press release announcing its financial results for the year ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1854270/000185427023000032/0001854270-23-000032-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.